- Home
- GCDT vs PULM Comparison
GCDT vs PULM Comparison
Compare GCDT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | PULM |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 6.1M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GCDT | PULM |
|---|---|---|
| Price | $0.36 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.4K | 16.8K |
| Earning Date | 05-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.33 | $1.16 |
| 52 Week High | $5.32 | $5.58 |
Technical Indicators
Market Signals| Indicator | GCDT | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 28.79 | 54.05 |
| Support Level | N/A | $1.59 |
| Resistance Level | $0.66 | $1.84 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.00 | 58.85 |
Price Performance
Historical ComparisonAbout GCDT Green Circle Decarbonize Technology Limited Ordinary Shares
Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).